Comparison · NCT03710603-bf76b992
Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): Progression Free Survival (PFS)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Velcade Lenalidomide Dexamethasone (VRd) vs Daratumumab + VRd (D-VRd): Progression Free Survival (PFS). Trial comparisons, record NCT03710603-bf76b992. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03710603-bf76b992
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.291 | 0.246 | 0.34 | wilson | |
| Risk in group 2 | 0.141 | 0.108 | 0.181 | wilson | |
| Risk difference, group 1 minus group 2 | 0.15 | 0.09 | 0.209 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.07 | 1.52 | 2.8 | log | |
| Odds ratio, group 1 over group 2 | 2.5 | 1.72 | 3.65 | log | |
| Number needed to treat, for one more participant with the outcome on Velcade Lenalidomide Dexamethasone (VRd) than on Daratumumab + VRd (D-VRd) | 6.66 | 4.78 | 11.1 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Velcade Lenalidomide Dexamethasone (VRd) | Arm A: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation. | 103 | 354 | OG000 |
| Group 2 | Daratumumab + VRd (D-VRd) | Arm B: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with subcutaneous daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by subcutaneous daratumumab in combination with lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation. | 50 | 355 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Progression Free Survival (PFS)
- Description
PFS was defined as duration from date of randomization to either progressive disease (PD)/death whichever occurred first. PD was defined as meeting any one of the following criteria: Increase of \>= 25 % in level of serum M-protein form lowest response value and absolute increase must be \>= 0.5 g/dL; Increase of \>=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \>=200 mg/24 hours; Only in participants without measurable serum and urine M-protein levels; increase of \>=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be \> 10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
- Time frame
- From the date of randomization to either progressive disease or death whichever occurred first, up to a maximum follow-up time of 54.41 months.
- Population
- Randomized population, intention-to-treat
Source ClinicalTrials.gov
Trial
- Title
- Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
- NCT number
- NCT03710603
- Phases
- PHASE3
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Velcade, Lenalidomide, dexamethasone
- Lead sponsor
- Stichting European Myeloma Network
- Results first posted
- 2024-12-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03710603?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03710603-bf76b992